Last Friday, Oracle (ORCL) said that it would increase its restructuring charge by another $700 million. Shares could face a further post-earnings selling slump in response to that news.
The database software giant will book another $700 million associated with layoffs. Management will record the figure in the consolidated statements of operations. It already logged $167 million in the quarter ended August 31, 2026, and $415 million in 2025.
Oracle likely took that step to offset its expensive AI buildout. Unfortunately, cutting staff that previously contributed to the firm’s output might worsen product development, operations, or customer support.
In the private credit market, Blue Owl (OWL) performed the worst in the financial segment. OWL stock lost 10.81% to close at $10.56, closing below the 50-day simple moving average. The firm previously reported that it would write down the loan value of Loparex to almost zero. Although the firm has over 780 loans outstanding, markets worry that more write-downs loom.
Apollo Management (APO) entered talks to acquire J&J’s (JNJ) orthopedics unit, according to WSJ on September 12. The medical devices sector is slumping. Shares of Stryker (SYK) and Medtronic (MDT) have mixed performance. The former lost over 21% YTD, while MDT stock trended higher.
If J&J sells its valuable orthopedic unit, it might hurt shareholder returns. The firm spent billions building the unit over the years.
